Non-Hodgkin lymphoma as primary bone tumor in a patient with B hepatic viral infection - case report

1. Cheson B et al. Monoclonal Antibody Therapy for B-Cell Non-Hodgkin’s Lymphoma. New England Journal of Medicine. 2008; 359:613-626.10.1056/NEJMra070887518687642Search in Google Scholar

2. Menon MP, Pittaluga S, Jaffe ES. The Histological and Biological Spectrum of Diffuse Large B-cell Lymphoma in the WHO Classification. Cancer J. 2012 September; 18(5):411–420.10.1097/PPO.0b013e31826aee97345851523006945Open DOISearch in Google Scholar

3. Kwak JY. Treatment of Diffuse Large B Cell Lymphoma. Korean J Intern Med. 2012; 27:369-377.10.3904/kjim.2012.27.4.369352923323269875Open DOISearch in Google Scholar

4. Ruzek KA, Wenger DE. The multiple faces of lymphoma of the musculoskeletal system. Skeletal Radiol. 2004; 33:1–8.10.1007/s00256-003-0709-y14605767Open DOISearch in Google Scholar

5. Caporale MF et al. Non-Hodgkin’s lymphoma: unexpected cause of shoulder pain. A systematic review of the literature. Muscles, Ligaments, and Tendons Journal. 2013; 3(3):236-239.Search in Google Scholar

6. Baar J, Burkes RL, Gospodarowicz M. Primary non-Hodgkin's lymphoma of bone. Semin Oncol. 1999 Jun; 26(3):270-275.Search in Google Scholar

7. Engels EA. Infectious Agents as Causes of Non-Hodgkin Lymphoma. Cancer Epidemiol Biomarkers Prev. 2007; 16:401-404.10.1158/1055-9965.EPI-06-105617337646Open DOISearch in Google Scholar

8. Zhang Y et al. Ultraviolet radiation exposure and risk of non-Hodgkin's lymphoma. Am J Epidemiol. 2007 Jun 1; 165(11):1255-1264.10.1093/aje/kwm02017327216Search in Google Scholar

9. Samir D, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies. Leukemia Research 37. 2013; 1107–1115.10.1016/j.leukres.2013.06.00723809055Search in Google Scholar

10. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumor-igenesis, and therapeutic opportunities. Blood. 2011; 117(6):1792-1798.10.1182/blood-2010-06-27581820959600Search in Google Scholar

11. Yang JD, Girotra M, Vaid A, Duarte-Rojo A. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention. J Ark Med Soc. 2013 Nov; 110(6):110-2.Search in Google Scholar

12. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63(8):803-43.10.2165/00003495-200363080-0000512662126Search in Google Scholar

13. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013 Jul; 57(3):209-14.10.1016/j.jcv.2013.03.01023562041Open DOISearch in Google Scholar

14. Lee IC, Huang YH, Chu CJ, Lee PC, Lin HC, Lee SD. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc. 2010; 73:156–60.10.1016/S1726-4901(10)70031-9Search in Google Scholar

15. Davis J. Preventing hepatitis B virus reactivation following immunosuppressive therapy. Intern Med J. 2008; 38:617, author reply 17-18.10.1111/j.1445-5994.2008.01652.x18715318Open DOISearch in Google Scholar

16. Changhong Liu et al. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Experimental and Therapeutic Medicine. 2013; 5:545-548.10.3892/etm.2012.850357014323403957Search in Google Scholar